Report of Foreign Issuer (6-k)
2020年5月26日 - 10:46PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
Report
of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under
the Securities Exchange Act of 1934
For
the Month of May 2020
011-36000
(Commission
File Number)
XTL
Biopharmaceuticals Ltd.
(Exact
name of Registrant as specified in its charter)
5
Badner St.
Ramat
Gan, Israel, 5218102
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒
Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
____
On
May 26, 2020, XTL Biopharmaceuticals Ltd. (the “Company”) announced that it will hold an Extraordinary General Meeting
of Shareholders on June 30, 2020 at 10:00 a.m. (Israel time) at the offices of the Company's attorneys, Doron Tikotzky Kantor
Gutman Nass & Amit Gross., 7 Metsada St., B.S.R Tower 4, 33 Floor, Bnei Brak, Israel. In connection with the meeting,
the Company furnishes the following documents:
|
1.
|
A
copy of the Notice and Proxy Statement with respect to the Company’s Extraordinary General Meeting of Shareholders describing
the proposal to be voted upon at the meeting, the procedure for voting in person or by proxy at the meeting and various other
details related to the meeting, attached hereto as Exhibit 99.1;
|
|
2.
|
A
form of Proxy Card whereby holders of ordinary shares of the Company may vote at the meeting without attending in person,
attached hereto as Exhibit 99.2; and
|
|
3.
|
A
form of Voting Instruction Card whereby holders of American Depositary Shares of the Company may vote at the meeting without
attending in person, attached hereto as Exhibit 99.3.
|
Exhibit
Index
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
XTL
BIOPHARMACEUTICALS LTD.
|
|
|
|
Date:
May 26, 2020
|
By:
|
/s/
Shlomo Shalev
|
|
|
Shlomo
Shalev
|
|
|
Chief
Executive Officer
|
3
XTL Biopharmaceuticals (NASDAQ:XTLB)
過去 株価チャート
から 11 2024 まで 12 2024
XTL Biopharmaceuticals (NASDAQ:XTLB)
過去 株価チャート
から 12 2023 まで 12 2024